Clinical trial
Phase II Study of Fractionated 90Y Ibritumomab Tiuxetan (Zevalin)
NCT01493479 is registered in ClinicalTrials.gov with The Christie NHS Foundation Trust as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Phase II Study of Fractionated 90Y Ibritumomab Tiuxetan (Zevalin)
- Lead sponsor
- The Christie NHS Foundation Trust
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- June 6, 2007
- Completion date
- November 6, 2015
- Enrollment
- 76 (actual)
- Sites
- 7
Conditions
As the registry lists them; a condition with its own page is linked.
follicular lymphoma